We have updated our Psychedelic Company Financing Tracker to reflect activity in Q3 2024. You can explore the interactive charts here.
2024 got off to a roaring start, with over $600M raised in the first half of the year. However, the majority of that inflow happened in Q1, with a 60% drop-off in Q2.
Q3 has seen funding slow even further, with inflows down to around $37.5M for the quarter: a 90% decrease since Q1 and a nearly 80% drop from Q2. Aside from Q4 2023, when inflows dropped to a low of just over $16M, we haven’t seen levels like this since Q1 2020.
To continue reading, please log in or join Pα+…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
